US Stock Alert: VeraDermics Plunges on November 13 – Losses Expand, Major Shareholders Reduce Holdings, All Positive News Already Priced In

VeraDermics November 13 Sharp Decline Analysis

Keywords: widened losses, major shareholder reduction, no more positive news

1. On November 10, the company released its Q3 2026 financial report. Net losses for the first three quarters reached $71.733 million, significantly higher than $48.148 million in the same period last year. The company has no approved commercial products yet, and its business relies on the subsequent clinical and regulatory progress of VDPHL01.

2. On November 12, a shareholder holding 10% of the shares proposed to sell their VeraDermics holdings, increasing stock supply pressure.

3. After VDPHL01 Phase III clinical trial positive data was announced on October 19, the share price surged for a time, but there has been no new positive company news since then. Early event-driven funds have taken profits, amplifying stock price volatility.

(Disclaimer: This content is generated by AI technology based on publicly available information for reference only and does not constitute investment advice.)